By Kathryn Calkins
Staff Writer

Aviron on Saturday presented positive results of a Phase III trial of its FluMist influenza vaccine in healthy working adults. But the lack of statistical significance on an efficacy end point - not the purpose of the trial - could cause investors some pause come Monday morning.